ما هو العلاج الNIPT؟
ديسمبر 16, 2025
ما هو إكسوم؟
ديسمبر 16, 2025ما هو العلاج الNIPT؟
ديسمبر 16, 2025ما هو إكسوم؟
ديسمبر 16, 2025
ما هو العلاج الNIPT؟
ما هو اختبار NIPT؟
NIPT (اختبار ما قبل الولادة غير الجراحي) هو اختبار فحص غير جراحي قبل الولادة يقوم بتحليل الحمض النووي الجنيني الخالي من الخلايا (cfDNA) المنتشر في دم الأم الحامل لتوفير معلومات حول صحة الكروموسومات للطفل. يُفضل NIPT بشكل خاص نظرًا لدقته العالية في اكتشاف تشوهات عدد الكروموسومات مثل التثلث الصبغي 21 (متلازمة داون)، والتثلث الصبغي 18 (متلازمة إدواردز)، والتثلث الصبغي 13 (متلازمة باتو). يمكن إجراء هذا الاختبار بدءًا من الأسبوع العاشر من الحمل وما بعده ولا يتطلب سوى أنبوب دم واحد، ولا يشكل أي خطر على الأم أو الطفل.
RapidNIPT هي العلامة التجارية لخدمة NIPT التي يقدمها مركز تقييم الأمراض الجينية Genoks. يتم تنفيذ جميع عمليات اختبار RapidNIPT من خلال أنظمة تقنية متقدمة ومؤتمتة بالكامل في مختبرات Genoks في أنقرة. تم تطوير RapidNIPT باستخدام أحدث أنظمة التحليل الجيني المعتمدة في جميع أنحاء العالم، وهو يوفر تجربة فحص ما قبل الولادة آمنة وشاملة وذات أسس علمية. باستخدام RapidNIPT، يمكن للعائلات اتخاذ قرارات أكثر استنارة أثناء الحمل والحصول على معلومات مبكرة عن المخاطر المحتملة.
ما هو RapidNIPT؟
RapidNIPT is a dedicated NIPT test brand offered by the Genoks Genetic Diseases Assessment Center. All analyses are performed using high-technology systems within a fully automated laboratory infrastructure in Ankara. The process is conducted in accordance with high sensitivity and reliability standards, using methods that minimize human intervention.
RapidNIPT makes the genetic evaluation process patient-focused, fast, and practical. Test results are assessed by experienced medical genetics specialists and are presented to families together with professional genetic counseling.
How Is the RapidNIPT Test Performed?
The RapidNIPT test can be applied from the 10th week of pregnancy onward. The procedure is quite simple:
- A single tube of blood is collected from the expectant mother’s arm, just like a routine blood test.
- cfDNA (cell-free DNA) present in the blood sample is analyzed. cfDNA is genetic material that passes from the placenta into the mother’s bloodstream during pregnancy and provides information about the fetus.
- cfDNA is examined using advanced molecular analysis techniques.
Through this approach, fetal genetic data can be evaluated and a risk analysis for chromosomal abnormalities can be performed.
Down Syndrome and NIPT
The NIPT test is a reliable method particularly used in the assessment of common chromosomal abnormalities such as Down syndrome (Trisomy 21). Down syndrome results from the presence of an extra copy of chromosome 21 and is one of the most frequently observed chromosomal conditions during pregnancy.
Within the scope of screening for Down syndrome risk, RapidNIPT provides families with valuable information. In addition, evaluations can also be performed for other chromosomal abnormalities such as Trisomy 18 and Trisomy 13.
RapidNIPT and cfDNA Analysis
The focus of the RapidNIPT test is cfDNA found in the mother’s blood. cfDNA naturally circulates during pregnancy and reflects the genetic structure of the fetus. Thanks to this modern approach, risk assessment is performed without any invasive procedures, ensuring a safe process for both the mother and the baby.
Advantages of RapidNIPT
- Non-invasive method: Only a blood sample is required.
- Early applicability: Can be performed from the 10th week of pregnancy.
- Broad screening scope: Down syndrome and other chromosomal abnormalities can be evaluated.
- Fast results: Risk assessment can be completed within a short time.
- Expert support: Results are interpreted by physician medical genetics specialists.
Frequently Asked Questions
What is the NIPT test and what is it used for?
NIPT (Non-Invasive Prenatal Test) is based on the analysis of cfDNA in the mother’s blood and provides screening information for certain chromosomal abnormalities such as Down syndrome.
From which week of pregnancy can the NIPT test be performed?
It is generally performed from the 10th week of pregnancy. Suitability should be evaluated by a physician based on individual circumstances.
Is NIPT an invasive procedure?
No. It is performed using only a blood sample and is a non-invasive screening method.
Which chromosomal abnormalities does the NIPT test assess?
Primarily Down syndrome (Trisomy 21), as well as common autosomal aneuploidies such as Trisomy 18 and Trisomy 13, del/dup syndromes larger than 7 Mb, sex chromosome aneuploidies, and additionally DiGeorge syndrome in the PLUS package.
How accurate is the NIPT test?
It has high accuracy rates; however, it is a screening test and provides risk assessment rather than a definitive diagnosis. Diagnostic tests may be recommended if necessary.
How long does it take to receive the results?
RapidNIPT results are reported within 3 to 5 business days, while RapidNIPTPlus results are reported within 7 to 10 business days.
In which situations might a result not be obtained?
Low fetal fraction in early gestational weeks, multiple pregnancies, or technical reasons may affect the result. In such cases, a repeat sample may be requested.
ما هو RapidNIPT؟
RapidNIPT is Genoks’ NIPT brand. It offers cfDNA-based non-invasive screening, and results are evaluated by medical genetic specialist physicians together with clinical information.
Diğer Testlerimiz
